In late mitosis and G1, a complex of the essential initiation proteins Mcm2-7 are assembled onto replication origins to 'license' them for initiation. At other times licensing is inhibited by cyclin-dependent kinases (CDKs) and geminin, thus ensuring that origins fire only once per cell cycle. Here we show that, paradoxically, CDKs are also required to inactivate geminin and activate the licensing system. On exit from metaphase in Xenopus laevis egg extracts, CDK-dependent activation of the anaphase-promoting complex (APC/C) results in the transient polyubiquitination of geminin. This ubiquitination triggers geminin inactivation without requiring ubiquitin-dependent proteolysis, and is essential for replication origins to become licensed. This reveals an unexpected role for CDKs and ubiquitination in activating chromosomal DNA replication.
Non-proteolytic inactivation of geminin requires CDK-dependent ubiquitination.
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In late mitosis and G1, a complex of the essential initiation proteins Mcm2-7 are assembled onto replication origins to 'license' them for initiation. At other times licensing is inhibited by cyclin-dependent kinases (CDKs) and geminin, thus ensuring that origins fire only once per cell cycle. Here we show that, paradoxically, CDKs are also required to inactivate geminin and activate the licensing system. On exit from metaphase in Xenopus laevis egg extracts, CDK-dependent activation of the anaphase-promoting complex (APC/C) results in the transient polyubiquitination of geminin. This ubiquitination triggers geminin inactivation without requiring ubiquitin-dependent proteolysis, and is essential for replication origins to become licensed. This reveals an unexpected role for CDKs and ubiquitination in activating chromosomal DNA replication.
For most eukaryotic cells, chromosomal DNA must be replicated only once in each cell cycle. This is ensured by separating DNA replication into two distinct phases: in the first phase, which normally occurs in late mitosis and early G1, replication origins are 'licensed' for a single initiation event by loading heterohexamers of the Mcm2-7 proteins, thus forming the pre-replicative complex (pre-RC; reviewed in refs 1, 2). The second phase occurs during S phase, when replication forks are initiated at licensed origins. As each origin initiates, Mcm2-7 are displaced from it. Thus, as long as the ability to license origins ceases before DNA replication commences, then no replication origin will initiate replication more than once.
There is considerable data to show that CDK activity late in the cell cycle is important for preventing inappropriate origin licensing and re-replication of DNA 1, 2 . CDKs block licensing in a number of different ways that seem to vary from organism to organism 1, 2 . In metazoans, inappropriate licensing of replication origins late in the cell cycle is also inhibited by a small protein called geminin. In Xenopus eggs, geminin provides the major activity preventing DNA re-replication 3, 4 . Geminin specifically binds and inhibits the Cdt1/RLF-B component of the licensing system 3, 5, 6 .
The central role of Mcm2-7 regulation in preventing re-replication of DNA was first demonstrated in Xenopus egg extracts [7] [8] [9] . Two of these studies 7, 8 exploited the observation that the replication licensing system, as originally defined 10 , could be specifically inhibited by treating metaphase extracts with protein kinase inhibitors such as staurosporine and 6-dimethylaminopurine (6-DMAP) 11, 12 . Extracts treated with these inhibitors fail to load Mcm2-7 onto DNA but can efficiently replicate chromatin that has already been licensed. The ability to assay licensing activity using a 6-DMAP-based assay has permitted a systematic chromatographic fractionation of the Xenopus licensing system and the complete reconstitution of the licensing of Xenopus sperm chromatin with purified proteins 13, 14 .
Despite the effectiveness of this assay, it has remained unclear how 6-DMAP and staurosporine selectively inhibit the licensing system. Xenopus eggs are naturally arrested at meiotic metaphase II; on fertilization, a transient increase in cytosolic calcium induces them to complete mitosis and enter interphase. Similarly, extracts prepared from Xenopus eggs can be released into interphase by addition of calcium. As these extracts exit metaphase, the replication licensing system is rapidly activated (Fig. 1a, left) . 6-DMAP and staurosporine inhibit licensing if they are added to extracts arrested in metaphase (Fig. 1a,  right) ; however, no inhibition occurs when they are added to extracts already in interphase 11, 12 . Significantly, 6-DMAP and staurosporine only inhibit licensing at concentrations that inhibit the metaphaseinducing activity of Cdk1-cyclin B (maturation-promoting factor (MPF)) and are sufficient to cause extracts to spontaneously enter interphase 11, 12, 15 . These results raise the possibility that in Xenopus, the activation of the licensing system that normally occurs on exit from metaphase depends on CDK function.
To provide further evidence for this, we used roscovitine, an adenine derivative with a high specificity for CDKs 16 . We first determined the ability of roscovitine to inhibit MPF by titrating it into metaphasearrested extracts and monitoring if DNA was assembled into interphase nuclei in the absence of calcium stimulation. Roscovitine treatment (50-200 µM) inhibited MPF and caused spontaneous mitotic exit (Fig. 1b) , similar to the concentration of roscovitine required to block entry into mitosis in cycling extracts 16 . This corresponded to a decline in the total histone H1 kinase activity present in the extracts (Fig. 1c) . Metaphase extracts treated with ≥200 µM roscovitine before calcium addition were severely compromised in their ability to load Mcm7 onto chromatin (Fig. 1d) . As previously shown with 6-DMAP and staurosporine 11, 12 , inhibition of Mcm7 loading was only detected when roscovitine was added to metaphase extract, and did not occur when it was added to extract after release into interphase (Fig. 1d , far right-hand lane). The close correlation between the ability of roscovitine to inhibit MPF and replication licensing (also seen with 6-DMAP and staurosporine 11, 12 ) provides strong evidence that CDK activity is required for activation of the licensing system that normally occurs on exit from metaphase.
Metaphase extracts treated with 6-DMAP ('6-DMAP-treated extracts') not only lack licensing activity, but also contain an inhibitor of the Cdt1/RLF-B component of the licensing system 15 . The major inhibitor of licensing in Xenopus egg extracts is geminin, a specific inhibitor of Cdt1/RLF-B [3] [4] [5] [6] . We therefore asked whether geminin is responsible for the licensing defect seen in metaphase extract treated with CDK inhibitors. Gel filtration of metaphase extracts showed two peaks of geminin ( Fig. 2a) : a high-molecular-weight peak (fractions 3-5) consisting of complexes between geminin and Cdt1, and a lowmolecular-weight peak (fractions 7-10) consisting of free geminin 4 . On exit from metaphase, a proportion of the geminin was degraded (Fig. 2b) , but the remaining geminin no longer formed a complex with Cdt1 (Fig. 2a, ' + Ca 2+ ') 4 . When extract was supplemented with excess recombinant geminin (geminin DEL ) 5 after release into interphase, the recombinant geminin complexed with all of the Cdt1 in the extract (Fig. 2a, ' + Ca 2+ + r-geminin'). Previous experiments have shown that in early interphase, endogenous geminin is incapable of interacting with recombinant Cdt1 (ref. 4) . Together these results strongly suggest that in early interphase, endogenous Cdt1 is fully competent to bind to geminin and that the lack of complex formation is caused by a defect in the Cdt1-binding ability of geminin.
Next, we examined the effect of CDK inhibitors on complex formation. When metaphase extracts were treated with 6-DMAP before calcium addition to block activation of the licensing system, geminin levels remained high (Fig. 2b) and a significant proportion remained bound to Cdt1 ( Fig. 2a ; '+ 6-DMAP + Ca 2+ '). A similar effect was observed when metaphase extracts were treated with roscovitine before calcium addition (Fig. 2a '+ roscovitine + Ca 2+ 'and Fig. 2b) . Immunodepletion of the high-molecular-weight fractions 3-5 confirmed that geminin and Cdt1 were complexed together, as all the Cdt1 was co-depleted with anti-geminin antibodies (Fig. 2c, ' gem−') and all (c) Metaphase extracts were incubated for 15 min in the presence or absence of calcium and roscovitine, as indicated, before being used for a histone H1 kinase assay. Roscovitine concentrations were: 10, 20, 50, 100, 200, 500 and 1000 µM. (d) Metaphase extracts were supplemented with 3 mM 6-DMAP or various concentrations of roscovitine before addition of 0.3 mM calcium chloride ('metaphase + 6-DMAP + Ca 2+ ' or 'metaphase + rosco + Ca 2+ '). Alternatively, 6-DMAP or roscovitine were added after calcium addition ('metaphase + Ca 2+ + 6-DMAP' or 'metaphase + Ca 2+ + roscovitine'). Xenopus sperm were then added to the extract for 20 min before chromatin was isolated and immunoblotted for Mcm7.
the geminin was co-depleted with anti-Cdt1 antibodies (Fig. 2c , 'Cdt1− '). To confirm an essential role for CDKs in inactivating geminin, metaphase extracts were immunodepleted of Cdk1 before addition of calcium. Although some Cdt1 and geminin were co-depleted with the anti-Cdk1 antibodies (data not shown), the remaining Cdt1 was fully complexed to geminin (Fig. 2b , 'Cdk1− + Ca 2+ '). These Cdk1-depleted extracts were devoid of licensing activity, although licensing activity could be restored by addition of Cdt1 (data not shown). This result is consistent with earlier observations showing that immunodepletion of Cdk1 (Cdc2) from metaphase-arrested Xenopus extracts blocks subsequent DNA replication 17 .
To address whether the presence of active geminin explains the ability of 6-DMAP-treated extracts to inhibit licensing, we performed a functional assay for licensing inhibitors. As expected 4,15 , 6-DMAP-treated extract inhibited the licensing activity of normal interphase extract (Fig. 3a , '6-DMAP extract'). However, immunodepletion of geminin from the 6-DMAP-treated extract almost completely abolished its inhibitory activity, whereas control depletion with non-immune . (c) Gel filtration fractions 3-5 from extract supplemented with 500 µM roscovitine before calcium chloride addition were pooled together. They were then immunodepleted with antibodies against geminin, Cdt1 or non-immune (NI) antibodies. The supernatants from the precipitations (representing immunodepleted extract) and proteins eluted from the antibodies in 100 mM glycine at pH 2.5 (precipitate) were then separated by SDS-PAGE and immunoblotted for geminin and Cdt1. The starting pool without any immunodepletion is also shown (pool).
antibodies had no effect. This suggests that geminin is the major licensing inhibitor in 6-DMAP-treated extract. When 6-DMAP-treated extract was supplemented with recombinant Cdt1 to titrate out the inhibitory activity of geminin, the ability of the extract to support DNA replication was restored (Fig. 3b) . These results suggest that the only replication defect in 6-DMAP-treated extracts is the presence of active geminin. Analogous replication assays could not be performed with roscovitine-treated extracts because in addition to inhibiting replication licensing, roscovitine also inhibits CDK activity required for the initiation of DNA replication (ref. 16 and data not shown). Instead, we investigated whether the addition of recombinant Cdt1 to licensing-defective extracts would restore their ability to load Mcm2-7 onto chromatin. Metaphase extracts were treated with 6-DMAP or roscovitine before addition of calcium, and as expected these extracts did not load Mcm7 onto chromatin (Fig. 3c) . However, subsequent addition of recombinant Cdt1 to the extract induced efficient Mcm7 loading. Taken together, these results suggest that on exit from metaphase, CDKs have an essential function in inactivating geminin and activating the licensing system. This contrasts with other well-documented roles of CDKs in inhibiting the licensing system at other cell cycle stages 1, 2 .
One known function of CDKs on exit from metaphase is activation of the APC/C 18, 19 , and it has been shown that addition of 6-DMAP to metaphase extracts prevents the APC/C-mediated proteolysis of cyclin B 15, 20 . Therefore, we investigated whether inactivation of geminin is dependent on APC/C function by using a peptide representing the consensus APC/C-recognition sequence (D-box peptide), which is a competitive inhibitor of the APC/C 21 . Addition of the D-box peptide to metaphase extracts before addition of calcium blocked the degradation of cyclin B and geminin, and blocked the ability of the extracts to load Mcm7 onto chromatin (Fig. 4a) . Gel filtration of D-box peptidetreated extract demonstrated that Cdt1 and geminin were still complexed together (Fig. 4c) . Thus, the D-box peptide prevents activation of the licensing system and inactivation of geminin that normally occur on exit from mitosis. Similar results were obtained by supplementing extracts with a mutant form of ubiquitin (ubiquitin K48R) that prevents formation of polyubiquitin chains (Fig. 4b, c) . These results suggest that the ubiquitin ligase activity of the APC/C (which in turn is dependent on CDK activity) is essential for inactivating geminin on metaphase exit. The effect of ubiquitin K48R suggests that polyubiquitination through lysine 48 is most probably required for geminin inactivation. Proteins known to be ubiquitinated by the APC/C, such as cyclin B and securin, are subsequently degraded by the 26S proteasome. Therefore, MG-132, a potent inhibitor of the 26S proteasome, was used to investigate whether proteasome function is required for the inactivation of geminin. Although proteasome-mediated degradation of cyclin B and geminin was inhibited by MG-132 (Fig. 4d) , it had no effect on the activation of the licensing system (Fig. 4e) or on the inactivation of geminin (Fig. 4h) . Similar results were obtained with epoxomicin, another high-specificity proteasome inhibitor (Fig. 4g, h ). Remarkably, metaphase extracts treated with MG-132 still supported efficient DNA replication (Fig. 4f) ; under these conditions, Cdk1-cyclin B activity is inhibited by ubiquitination in the absence of proteolysis (ref. 22 and data not shown). Taken together, the results presented here suggest that although activity of the APC/C is essential for geminin inactivation, proteasome-mediated degradation is not.
Geminin has previously been reported to be ubiquitinated by the APC/C on exit from metaphase 5 . As we have shown that APC/C activity is essential for geminin inactivation, we investigated whether geminin itself is an essential APC/C substrate in this process. We prepared two forms of 35 S-labelled recombinant geminin: the first wild type, and the second with a deletion of nine amino acids in the APC/C recognition motif (geminin DEL ) so that it is no longer a substrate for the APC/C 5 . To prevent degradation of the wild-type recombinant protein, proteolysis was inhibited with MG-132. On incubation in Xenopus extract exiting from mitosis, approximately half of the recombinant wild-type geminin was inactivated so that it did not associate with Cdt1 (Fig. 5a, top) . In contrast, the geminin DEL mutant was completely refractory to inactivation (Fig. 5a, bottom) . This suggests that APC/C-mediated ubiquitination of geminin is required for its inactivation.
No significant proportion of the inactive geminin detected in interphase extracts was itself ubiquitinated, as ubiquitination would cause an increase in molecular weight of >8K, a change clearly not observed (Figs 2 and 4 , and data not shown). As geminin forms octomeric or decameric complexes (ref. 4 and S. Shreeram, unpublished observations), we considered the possibility that inactive complexes of geminin contain a mixture of both ubiquitinated and non-ubiquitinated forms. However, examination by SDS-PAGE of gel filtration fractions containing 35 S-labelled wild-type geminin in the inactive complex identified no significant quantity of high-molecular-weight ubiquitinated geminin (Fig. 5a, right) .
Xenopus eggs contain high levels of isopeptidases that remove ubiquitin from proteins 23 , so an alternative explanation is that geminin is only transiently ubiquitinated on exit from metaphase, with de-ubiquitination leaving geminin locked into an inactive conformation. To test this idea, metaphase extracts supplemented with glutathione S-transferase (GST)-ubiquitin, recombinant geminin and MG-132 were released into interphase by calcium addition and incubated for various times. GST-tagged proteins were then collected on glutathione beads, separated by SDS-PAGE and immunoblotted with anti-geminin antibodies. Between 5 and 10 min after calcium release, a ladder of high-molecular-weight geminin was detected (Fig. 5b, left) . The lowest band in this ladder was ~70K, the expected size of geminin conjugated to GST-ubiquitin. By 30 min, this ladder had almost completely disappeared, suggesting that the geminin had been de-ubiquitinated (proteolysis having been blocked by MG-132). A similar ladder, although fainter, was seen without addition of recombinant geminin, suggesting that the same reaction is occurring on endogenous geminin (Fig. 5b,  right) . The intensity of the ladder was increased by addition of ubiquitin aldehyde, an inhibitor of de-ubiquitinating enzymes.
The results presented here provide strong support for the model outlined in Fig. 5c . In metaphase-arrested Xenopus egg extracts, geminin binds and inhibits Cdt1, whereas active CDKs reduce the affinity of the origin recognition complex (ORC) and Cdc6 for chromatin. After calcium addition, APC/C is activated, and this activation requires ongoing CDK activity [18] [19] [20] . The active APC/C then polyubiquitinates geminin 5 . Some of the ubiquitinated geminin is degraded, but this is not essential for activation of the licensing system. For the licensing system to be activated, the remaining geminin must be inactivated. This occurs as a consequence of APC/C-mediated ubiquitination. The polyubiquitination of geminin is only transient, but after de-ubiquitination, geminin remains in an inactive state. One possible way this could occur could be through a second covalent modification that is dependent on earlier ubiquitination of geminin; alternatively, ubiquitination could force geminin into an inactive conformation. Thus geminin joins an expanding collection of proteins whose activity is known to be regulated by ubiquitination independently of proteolysis 24, 25 .
This model explains how treatment of metaphase extracts with CDK inhibitors can provide a functional assay for licensing system components 7, 8, 11, 12, 14 . Reconstitution experiments based on this assay have shown that Xenopus sperm nuclei must be incubated with a combination of nucleoplasmin, ORC, Cdc6, Cdt1 and Mcm2-7 before the chromatin becomes competent to replicate when transferred to 6-DMAP-treated extract 13, 14 .
The inhibitory role of CDKs on replication licensing and DNA rereplication has been extensively documented 1, 2 . In contrast, we show here that in Xenopus egg extracts, CDKs are required to inactivate geminin on exit from metaphase, thus having an essential positive function in replication licensing. There are, however, precedents for CDKs having a positive function in this process. During Drosophila endocycles, Mcm2-7 are re-loaded onto DNA only as cyclin E levels rise at the start of each endocycle 26 . In cell-free extracts prepared from human cells, the loading of Mcm2 onto DNA is stimulated by cyclin E/Cdk2 (ref. 27) . It is possible that these observations also reflect CDK-dependent ubiquitination and inactivation of geminin, as the function of other SCF-type ubiquitin ligases also depends on CDK activity. The ubiquitination-dependent inactivation of geminin may therefore be a widespread means of regulating the licensing system.
METHODS
Preparation and use of egg extracts. Metaphase-arrested and interphase lowspeed supernatant Xenopus egg extracts were prepared as described 28 . All extracts were supplemented with 250 µg ml −1 cycloheximide, 25 mM phosphocreatine and 10 µg ml −1 creatine phosphokinase before use, and incubations were performed at 23°C. Xenopus sperm nuclei were demembranated with lysolecithin, as described 28 , and stored frozen at −80°C. For DNA synthesis experiments, sperm nuclei were incubated at a final concentration of 3 ng DNA per µl extract (∼1,000 nuclei per µl), and extracts (typically 10 µl) were supplemented with 50 µCi ml −1 α 32 P-dATP. After a 90-min incubation, DNA synthesis was assessed by TCA precipitation, as described 28 . The histone H1 kinase assay was performed essentially as described 29 . Gel filtration of Xenopus extracts was performed as described 4 .
Immunodepletion of Cdk1 from extract was performed essentially as described 28 . Affinity-purified anti-Cdk1 antibody was coupled to protein A-agarose beads at 15 mg antibody ml −1 beads and washed in EDB-S buffer (50 mM Hepes at pH 7.6, 50 mM potassium chloride, 2 mM dithiothreitol (DTT), 0.4 mM magnesium chloride, 0.4 mM EGTA, 10% sucrose, and 10 µg ml −1 each of leupeptin, pepstatin and aprotinin). Metaphase-arrested extract was mixed with 0.2 volumes of antibody beads for 1 h at 4°C, after which the beads were removed. The process was repeated two more times. Immunoblotting of the depleted extract showed no detectable Cdk1 or cyclin B. The depleted extract spontaneously assembled sperm DNA into interphase nuclei, consistent with the removal of MPF activity.
Recombinant protein and antibodies. Recombinant 6×His-tagged Xenopus Cdt1 30 was produced as described 14 . 35 S-labelled geminin was produced from pET28(a) plasmid DNA containing wild-type geminin or geminin DEL (ref. 5) using the TnT coupled reticulocyte lysate System (Promega, Madison, WI) according to the manufacturer's instructions. Antibodies against Xenopus geminin, Cdt1 and Mcm7 were as previously described 3 . Antibody against Xenopus cyclin B2 was a kind gift of T. Hunt. The D-box peptide (RRTALGDVTNKVSE), as described 21 , was a kind gift of J. Hutchins and P. Clarke. Antibody against Cdk1 was raised against a C-terminal peptide (CFDDLDKSSLPANQIRN) and was a kind gift of J. Walter and T. Prokhorova. Immunoblots were developed using SuperSignal west pico chemiluminescent substrate (Pierce, Rockford IL) and pre-flashed film.
Chromatin isolation. For immunoblotting experiments, extracts were treated in various ways, then 20-µl aliquots were supplemented with demembranated sperm nuclei at a final concentration of 10 ng DNA per µl extract (~3,000 nuclei per µl). After a 20-min incubation, each reaction was diluted in 500 µl NIBA (50 mM potassium chloride, 50 mM Hepes KOH at pH 7.6, 5 mM magnesium chloride, 2 mM DTT, 0.5 mM spermidine, 0.15 mM spermine, 2.5 mM Mg-ATP, and 1 µg ml −1 each of leupeptin, pepstatin and aprotinin) supplemented with 0.1% Triton X-100 and under-layered with 100 µl of the same buffer containing 15% sucrose. The chromatin was pelleted at 6,000g in a swinging bucket rotor at 4°C before SDS-PAGE and immunoblotting.
Licensing inhibition assay. Licensing inhibition assays were performed essentially as described 4 . Briefly, fractions of interest (1.5 µl) were incubated with 0.5 µl interphase extract and 0.3 µl of sperm nuclei (80 ng DNA per µl) for 30 min. The degree of licensing was then assessed by addition of 6 µl interphase extract containing 1.5 ng µl −1 geminin DEL and α 32 P-dATP and incubation for a further 90 min; total DNA synthesis was measured by TCA precipitation as described above.
Ubiquitination assay. 20 µl metaphase-arrested extract was supplemented with 800 µM MG-132 and 25 µg ml −1 GST-ubiquitin, 50 µg ml −1 ubiquitin aldehyde, or 5 µg ml −1 recombinant wild-type geminin as appropriate. Extracts were released into interphase with 0.3 mM calcium chloride and incubated at 23°C. Reactions were stopped by dilution in 30 µl of ice-cold bead-binding buffer (50 mM potassium phosphate at pH 8 containing 0.05% Tween-20) supplemented with 150 mM sodium chloride, 10 mM N-ethyl maleimide and 10 µl glutathione beads. After incubation for 30 min on a rotating wheel at 4°C, the beads were washed three times in 200 µl bead-binding buffer containing 500 mM sodium chloride and once in 200 µl bead-binding buffer without sodium chloride. Beads were then resuspended in SDS gel-loading buffer before SDS-PAGE and immunoblotting for geminin.
